Accordingly, we examined the activation state of RhoA and its downstream actions in the PBMCs of lupus patients and assessed the consequences of RhoA pathway inhibition on selected type I IFN-induced genes relevant to immune dysregulation. This evidence concerns the gene RHOA and systemic lupus erythematosus.